CFB
2-CHLORO-9-(2-DEOXY-2-FLUORO-B -D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE
Created: | 2005-07-14 |
Last modified: | 2021-03-01 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 31 |
Chiral Atom Count | 4 |
Bond Count | 33 |
Aromatic Bond Count | 10 |
Chemical Component Summary | |
---|---|
Name | 2-CHLORO-9-(2-DEOXY-2-FLUORO-B -D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE |
Synonyms | CLOFARABINE |
Systematic Name (OpenEye OEToolkits) | (2R,3R,4S,5R)-5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol |
Formula | C10 H11 Cl F N5 O3 |
Molecular Weight | 303.677 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | Clc1nc(c2ncn(c2n1)C3OC(C(O)C3F)CO)N |
SMILES | CACTVS | 3.341 | Nc1nc(Cl)nc2n(cnc12)[CH]3O[CH](CO)[CH](O)[CH]3F |
SMILES | OpenEye OEToolkits | 1.5.0 | c1nc2c(nc(nc2n1C3C(C(C(O3)CO)O)F)Cl)N |
Canonical SMILES | CACTVS | 3.341 | Nc1nc(Cl)nc2n(cnc12)[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | c1nc2c(nc(nc2n1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N |
InChI | InChI | 1.03 | InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1 |
InChIKey | InChI | 1.03 | WDDPHFBMKLOVOX-AYQXTPAHSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank ID | DB00631 |
---|---|
Name | Clofarabine |
Groups |
|
Description | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. |
Synonyms |
|
Brand Names |
|
Indication | For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use. |
Categories |
|
ATC-Code | L01BB06 |
CAS number | 123318-82-1 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
DNA | - | unknown | other/unknown |
Ribonucleoside-diphosphate reductase subunit M2 B | MGDPERPEAAGLDQDERSSSDTNESEIKSNEEPLLRKSSRRFVIFPIQYP... | unknown | inhibitor |
Ribonucleoside-diphosphate reductase subunit M2 | MLSLRVPLAPITDPQQLQLSPLKGLSLVDKENTPPALSGTRVLASKTARR... | unknown | inhibitor |
DNA polymerase alpha catalytic subunit | MAPVHGDDSLSDSGSFVSSRARREKKSKKGRQEALERLKKAKAGEKYKYE... | unknown | inhibitor |
Ribonucleoside-diphosphate reductase large subunit | MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSG... | unknown | inhibitor |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1750 |
PubChem | 119182 |
ChEMBL | CHEMBL1750 |
ChEBI | CHEBI:681569 |